Hot Topics

Poll

Why is it a big mistake to link funding of R&D costs with drug prices?:

St Jude's influenza patents, with US government rights

St Jude holds 24 patents with influenza in the specification, that also disclose US government rights. Some of these were discussed here: http://keionline.org/node/2188

PAT. NO. Title
1 8,574,592 Modified influenza virus for monitoring and improving vaccine efficiency
2 8,551,481 Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody
3 8,309,099 DNA transfection system for the generation of negative strand RNA virus

CDC FOIA regarding intellectual property on avian flu intellectual property rights

Our 2009 FOIA request, and 42 pages of CDC emails debating what to give us.

http://keionline.org/misc-docs/FOIA/14-01041-cdc-foia-frequest-2009.pdf

The February 17, 2015 cover letter from CDC.
http://keionline.org/sites/default/files/CDC_17feb2015_FOIA_CoverLetter.pdf

The 184 page CDC foia response, which we received in February 2015. Note that we were particularly interested in the patent issues related to reverse genetics.

KEI Special 301 supplemental comments: Compulsory Licensing not restricted to "Emergencies" or "Measure of Last Resort"

At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: http://keionline.org/ustr/special301).

KEI's supplemental comments in USTR 301: Online pharmacies, parallel trade and counterfeit drugs

At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: http://keionline.org/ustr/special301).

KEI's Feb 27, 2015 Supplemental Comments to USTR Regarding Research and Development

At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: http://keionline.org/ustr/special301).

WTO TRIPS Council (February 2015): EU mounts defense of tobacco plain packing measures in the Republic of Ireland and the UK

The following statement was delivered by the European Union on Tuesday, 24 February 2015 at the WTO TRIPS Council during discussions on "Concerns with respect to proposals for plain packaging of tobacco products in the United Kingdom and Ireland".

A few reactions to the USTR Special 301 Hearing

On Wednesday February 24, 2015, the United States Trade Representative (USTR) Special 301 Committee held its annual public meeting following written comments sent earlier by trade associations, corporations and a few public interest groups that follow trade and intellectual property.

KEI comments at February 24, 2015 USTR Special 301 Hearing

On February 24, 2015, the USTR convened the Special 301 Review, taking testimony almost exclusively from witnesses representing large corporate rights holders. Over the course of the three-and-a-half hour hearing, groups such as Phrma, NAM, IPO, and the misleadingly-named Alliance for Fair Trade with India (an alliance comprised of groups such as Phrma, NAM, MPAA and many other similar groups) as well as foreign-owned multinational Bridgestone, pushed for the watch-listing of countries that fail to implement TRIPS+ measures.

WTO TRIPS Council (February 2015): Bangladesh statement (on behalf of LDC Group)- Extension of the 2016 transitional period

On Tuesday, 24 February 2015, Bangladesh, on behalf of the LDC Group, presented the submission of the LDC Group on an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for LDC Members for Certain Obligations with Respect to Pharmaceutical Products in the following impassioned statement.

ANY OTHER BUSINESS

EXTENSION OF THE TRANSITION PERIOD UNDER ARTICLE 66.1 OF THE TRIPS AGREEMENT FOR LEAST-DEVELOPED COUNTRY MEMBERS FOR CERTAIN OBLIGATIONS WITH RESPECT TO PHARMACEUTICAL PRODUCTS

Mr. Chair

WTO TRIPS Council (February 2015): LDC Group statement on Non-Violation and Situation Complaints

On Tuesday, 24 February 2015, Bangladesh, on behalf of the LDC Group delivered the following statement on non-violation and situation complaints.

AGENDA 6: NON-VIOLATION AND SITUATION COMPLAINTS

Mr. Chairman,

I am taking floor on behalf of the LDC group.

LDCs are concerned that non-violation and situation complaints may pose unnecessary problems to LDCs which can be otherwise avoidable if we do not implement this provision under TRIPS.

WTO TRIPS Council (February 2015): LDC request for extension of the transitional period for pharmaceutical products

The World Trade Organization (WTO) is convening the TRIPS Council from Tuesday, 24 February 2015 to Wednesday, 25 February 2015. As mentioned in a previous piece, Norway and the United States "have submitted a written request for the inclusion of the topic, "Intellectual Property and Innovation: Women And Innovation" (Source: WTO TRIPS Council-February 2015- Norway and the United States bring gender mainstreaming to the fore-Women and Innovation, http://keionline.org/node/2167).

WTO Trade Policy Review of the United States: USTR deflects questions from India on compulsory licensing (December 2014)

On 16 December 2014 and 18 December 2014, the World Trade Organization (WTO) undertook a trade policy review of the United States of America. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM).

Human Rights Council Social Forum 2015: Intervention of Knowledge Ecology International

20 February 2015

In accordance with Human Rights Council resolution A/HRC/RES/26/28, the Human Rights Council convened the 2015 Social Forum at the United Nations Palais des Nations in Geneva from 18-20, February 2015 with a focus on "access to medicines in the context of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, including best practices in this regard."

Save the Date- 19 February 2015- Fire in the Blood- Screening co-sponsored by KEI/MSF-Access Campaign

The Human Rights Council's 2015 Social Forum will take place from 18 February 2015 to 20 February 2015 at the Palais des Nations in Geneva, Switzerland.

As requested by the Council in the above-mentioned resolution, the 2015 Social Forum will focus on "access to medicines in the context of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, including best practices in this regard ". (Source: http://www.ohchr.org/EN/Issues/Poverty/SForum/Pages/SForum2015.aspx).

Syndicate content